Rebif recombinant interferon beta-1a data

At the American Neurological Association meeting in San Diego, Ares-Serono presented positive results from its double-blind Phase III trial of Rebif in 560 patients with relapsing-remitting MS. Patients with

Read the full 291 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE